Epitalon is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.
Status as of July 14, 2026
Epitalon, also written epithalon or epitalone, is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) built in Russia across the 1980s and 1990s as a defined stand-in for a crude pineal-gland extract called epithalamin. The honest bottom line belongs up front: it has never been approved as a drug by the FDA or the European Medicines Agency, is not a recognized dietary ingredient, and circulates as an unapproved research chemical, so its anti-aging and telomere claims read as preliminary hypotheses rather than established medicine.
Epitalon is a Russian-developed synthetic tetrapeptide (Ala-Glu-Asp-Gly, C14H22N4O9, ~390 Da) that carries no FDA or EMA approval and circulates as an unapproved research chemical.
Structurally Epitalon is deliberately minimal: a linear tetrapeptide of four residues joined by three peptide bonds in the fixed order alanine-glutamic acid-aspartic acid-glycine (AEDG). Two acidic side chains leave the molecule net negatively charged and highly water soluble at physiological pH, which is why it is prepared as a solution, and its very short half-life reflects rapid cleavage by peptidases in blood and tissue.
Epitalon is a linear tetrapeptide (Ala-Glu-Asp-Gly, CAS 307297-39-8) whose two acidic residues make it water-soluble and whose small size gives it a biological half-life measured in minutes.
Epithalamin is not a single molecule but a crude peptide preparation extracted from cattle pineal glands, a mixture of small polypeptides studied in Soviet and Russian gerontology for proposed neuroendocrine and anti-aging effects. Epitalon is the deliberate simplification of that messy extract into one reproducible sequence, Ala-Glu-Asp-Gly, chosen on the hypothesis that this short fragment carries the active fraction. Being derived from a natural extract lends it no validation: it inherits the same thin, single-group evidence base as the epithalamin work it descended from.
Epitalon is a synthetic Ala-Glu-Asp-Gly tetrapeptide distilled from epithalamin, a crude cattle-pineal extract, and it inherits that extract's thin, largely single-group evidence base rather than gaining independent validation.
Epitalon is tied primarily to Professor Vladimir Khavinson, a Russian gerontologist who directed the St. Petersburg Institute of Bioregulation and Gerontology and led its work on short peptide bioregulators. The central caveat for anyone weighing the peptide is one of evidence concentration: the great majority of supportive studies come from Khavinson and his immediate collaborators, with sparse independent replication and essentially no large controlled human trials from outside groups.
Epitalon was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, and the majority of its supportive evidence originates from that same lineage with little independent replication.
Epitalon did not surface in the Western pharmacology mainstream; it grew out of a distinctly Soviet school that treated short peptides as bioregulators able to restore tissue function, pursued with far less of the double-blind, multi-center trial infrastructure that dominated the West at the time. Prevailing hypotheses linking the pineal gland's declining melatonin output to aging made a pineal-derived peptide fit a popular theoretical frame, and the earlier epithalamin work supplied both the rationale and the reported effects that motivated distilling it into a defined sequence.
Epitalon emerged from Soviet and post-Soviet peptide-bioregulator research between the 1970s and 2000s, a tradition with different validation norms than Western pharmacology, which is part of why its claims never entered approved mainstream medicine.
The founding aim was narrow: capture, in one manufacturable molecule, the anti-aging and neuroendocrine effects researchers believed the pineal extract epithalamin held, with later work extending that ambition to claims about activating telomerase and lengthening telomeres in cultured cells. A separate, practical driver was manufacturability, since a defined synthetic tetrapeptide sidesteps the batch variability and contamination concerns of an animal-tissue extract. Those original laboratory aims sit well below what current marketing often implies, which overstates preliminary cell and animal findings as proven human anti-aging benefit.
The original goal was to reproduce epithalamin's proposed anti-aging effects in one standardized synthetic tetrapeptide, and the telomerase-lengthening claims driving current marketing rest on cell-culture findings, not proven human benefit.
Epitalon holds no approved drug status anywhere: it has not been reviewed or cleared by the FDA, the European Medicines Agency, or comparable bodies to treat or prevent any condition, and it does not meet the definitions that would let it be sold lawfully as a dietary supplement. It circulates instead as a research chemical, a label meaning it is sold nominally for laboratory use and explicitly not for human consumption, a framing often used to sidestep medicine-grade safety and approval requirements. The practical consequence is that identity, purity, sterility, and dose accuracy go unverified, and independent testing has repeatedly found peptide products underdosed, mislabeled, or adulterated.
Epitalon has no FDA, EMA, or comparable drug approval and does not qualify as a dietary ingredient, so it is sold as an unapproved research chemical whose identity, purity, and dosing are unverified.
The core difference is one of definition and scale: Epitalon is a single, precisely specified four-amino-acid molecule, while its precursor epithalamin is a natural extract holding a mixture of many small peptides that cannot be fully characterized. Solid-phase synthesis gives the tetrapeptide a reproducibility the extract lacks, a real advantage for study design, but a cleaner molecule is not automatically a more effective or safer one. Distilling the blend down to one sequence trades away whatever the extract's other components contributed, and whether the fragment matches epithalamin's reported effects in living systems stays unresolved.
| Criteria | Epitalon (synthetic) | Epithalamin (natural extract) |
|---|---|---|
| Composition | One defined tetrapeptide (Ala-Glu-Asp-Gly) | Mixture of many small peptides, uncharacterized |
| Source | Solid-phase chemical synthesis | Extracted from cattle pineal glands |
| Reproducibility | Consistent, specified purity | Batch-to-batch variation, contamination risk |
| Evidence | Shares the same thin, single-group base | Reported effects that motivated the synthetic |
Epitalon is one defined synthetic tetrapeptide while epithalamin is an uncharacterized cattle-pineal extract, and the synthetic's reproducibility does not prove it reproduces the extract's reported biological effects.
Educational use only. This article describes what the published scientific and clinical literature reports about Epitalon. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
